NASDAQ · ABSI
Healthcare · Biotechnology
$10.17
Up+$0.78 (+8.31%)
Updated Nov 7, 2026, 8:22 AM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABSI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
ABSI closed at $10.17 after 21 trading sessions, up 0.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $9.83 | $10.255 | $9.51 | $10.17 | 4.16M |
| Nov 5, 2026 | $10.03 | $10.13 | $9.00 | $9.39 | 5.12M |
| Nov 4, 2026 | $10.26 | $10.68 | $9.78 | $10.48 | 4.16M |
| Nov 3, 2026 | $10.025 | $10.66 | $9.85 | $10.00 | 2.72M |
| Nov 2, 2026 | $11.29 | $11.32 | $9.68 | $9.69 | 3.81M |
| Oct 30, 2026 | $11.41 | $11.80 | $10.4501 | $11.13 | 4.57M |
| Oct 29, 2026 | $11.97 | $12.5449 | $11.91 | $12.10 | 4.34M |
| Oct 28, 2026 | $10.55 | $11.89 | $10.43 | $11.88 | 5.83M |
| Oct 27, 2026 | $9.54 | $10.95 | $9.36 | $10.57 | 5.84M |
| Oct 26, 2026 | $9.20 | $9.76 | $9.03 | $9.45 | 3.37M |
| Oct 23, 2026 | $9.28 | $9.35 | $8.965 | $9.18 | 1.89M |
| Oct 22, 2026 | $9.69 | $9.95 | $8.93 | $9.37 | 3.71M |
| Oct 21, 2026 | $9.24 | $10.205 | $9.1137 | $10.04 | 5.35M |
| Oct 20, 2026 | $8.465 | $9.10 | $8.22 | $9.07 | 2.83M |
| Oct 19, 2026 | $8.69 | $8.96 | $8.395 | $8.54 | 2.76M |
| Oct 16, 2026 | $8.93 | $8.95 | $8.12 | $8.25 | 3.55M |
| Oct 15, 2026 | $8.43 | $8.945 | $8.23 | $8.88 | 3.4M |
| Oct 14, 2026 | $8.88 | $9.12 | $8.62 | $8.74 | 3.56M |
| Oct 13, 2026 | $9.445 | $9.66 | $9.00 | $9.10 | 3.05M |
| Oct 12, 2026 | $10.065 | $10.09 | $9.43 | $9.67 | 2.86M |
| Oct 9, 2026 | $9.20 | $10.3902 | $8.93 | $10.16 | 4.25M |
The latest Smart Investors Daily articles mentioning ABSI.
Company
Market Activity
Research & News
ABSI research
Company profile and research snapshot.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 29, 2026 | Jefferies | Buy | — |
| Oct 16, 2026 | Keybanc | Overweight | — |
| Oct 12, 2026 | JP Morgan | Overweight | — |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 3, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029. The compan
Yahoo · Nov 2, 2026
Key Takeaways10x Genomics fell 12% today as Twist Bioscience, PacBio and Absci led genomics tools stocks lower, and no news explains the drop. Illumina raised its full-year guidance last week, so weak lab demand looks like an unlikely reason for the selling.
Yahoo · Oct 30, 2026
Key TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s business.
Yahoo · Oct 30, 2026
Absci reported positive interim Phase 1 data for ABS-201 in pattern hair loss, including an estimated half-life of at least 65 days and timelines for proof-of-concept data in the second half of 2026 and full data in early 2027. The extended half-life suggests ABS-201 could be dosed infrequently, which matters for patient adherence, treatment convenience and potential real world uptake if later stage trials support its use. This article now examines how ABS-201's encouraging half-life profile...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABSI.
